## Special Issue

# Updates on Precision Medicine in Hematological Disorders

## Message from the Guest Editor

Due to the relative ease of sample acquirement and because of several technological advances, the field of hematology has seen a rapid growth in the implementation of personalized medicine. This has been especially true for the case of mutation profiling. with certain subtypes of hematological malignancies having specific management strategies. Additionally, because of the advances in transcriptomics, proteomics and metabolomics, it is possible for the field of hematology to further see advances in the direction of personalized medicine. We are pleased to invite you to submit papers with results on basic and clinical research regarding the prediction of malignant cell biology or of clinical outcomes. In this special issue, original research articles as well as reviews are welcome. Research areas may include, but are not limited to:

- genetics/genomics of hematological malignancies
- transcriptomics of hematological malignancies
- proteomics of hematological malignancies
- metabolomics of hematological malignancies
- experimental data regarding hematological malignancies
- the importance of the tumor microenvironment in hematological malignancies

## **Guest Editor**

Dr. Sergiu Pasca

Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj Napoca, Romania

## Deadline for manuscript submissions

closed (30 July 2022)



# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



## mdpi.com/si/107989

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



## About the Journal

## Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## **Editor-in-Chief**

## Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

## **Author Benefits**

## **High Visibility:**

indexed within Scopus, PubMed, PMC, Embase, and other databases.

## **Journal Rank:**

CiteScore - Q1 (Medicine (miscellaneous))

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

